Synthego, the genome engineering company, launched Eclipse. Eclipse is a new high-throughput cell engineering platform designed to accelerate drug discovery and validation by providing highly predictable CRISPR-engineered cells at scale through the integration of engineering, bioinformatics, and proprietary science. CRISPR-engineered cells have a wide range of applications in research and development including, neuroscience and oncology.
Bill Skarnes, PhD, Professor and Director of Cellular Engineering, The Jackson Laboratory and Synthego advisory board member, said: “By industrializing cell engineering, Synthego’s Eclipse platform will enable economies of scale, turning a historically complex process into one that is flexible, reliable, and affordable. Offering CRISPR edits at scale, similar to what Synthego did with sgRNA reagents, puts researchers on the cusp of being able to study thousands of genes and examine hundreds of variants of those genes. This allows scientists to more faithfully model the complexity of a human disease, which could lead to the development of therapeutic drugs or next-generation gene therapies for many serious diseases.”
The Eclipse platform is modular in design, allowing for fast deployment of upgrades or add-ons, engineered to use a cell-type agnostic process and immediately benefit researchers working with induced pluripotent stem (iPS) cells and immortalized cell lines. With the combination of machine learning and automation, the platform helps reduces costs and increase the scalability of engineered cell production.
Paul Dabrowski, CEO and Co-Founder, Synthego, said: “We are living in a new era of life sciences innovation – one that has added to DNA sequencing and being able to read out of biology, now being able to write into and engineer biology. We created our Eclipse platform at the convergence of science and technology to make genome editing more precise, scalable, and accessible. We are excited to expand our impact on advancing the life sciences innovation with the launch of this unique CRISPR-based platform.”